143 terms you will see in pathology, IHC and PET/CT reports and discharge summaries. A short definition for each, and a detailed explainer for the most common ones.
Medically reviewed by Dr. Tara Einullaeva, medical oncologist · 19 October 2026
Diagnosis and pathology
Biopsy
Removing a small piece of tissue or a sample of cells from a suspicious area so it can be examined under a microscope. A cancer diagnosis is not confirmed without one: the biopsy tells the pathologist whether it is cancer, what type, and which markers matter for treatment.
A biopsy that uses a wider, hollow needle to remove a thin cylinder of tissue. Unlike fine-needle aspiration, it keeps the tissue structure intact, so it is usually enough for a full pathology diagnosis plus immunohistochemistry and molecular testing.Read more
Fine-needle aspirationFNA
A biopsy that uses a thin needle and a syringe to draw out individual cells from a lump or lymph node. The sample goes for cytology. It is quick and gentle, but the tissue structure is lost, so a core needle biopsy is often still needed for a final diagnosis and marker testing.
Cytology
Looking at individual cells under a microscope, for example from a needle aspirate, a smear, or fluid drained from around the lungs or abdomen. Cytology can find cancer cells, but it usually tells less than histology about the tumor type and its markers.
HistologyPathology report, histopathology
Examining a piece of tissue under a microscope after it has been processed and stained. The pathology report is the foundation of a cancer diagnosis: it names the tumor type and grade and, after surgery, the size, the margins and how many lymph nodes are involved.
A second pathologist, often at a specialist lab, re-examines the existing slides and tissue blocks. It is worth doing when the diagnosis is uncertain or rare, or when treatment depends heavily on it. A review can confirm, refine or change the tumor type and marker results.Read more
Paraffin blockFFPE block
Tissue from a biopsy or surgery that has been preserved in formalin and embedded in wax. Thin slices are cut from it to make slides. The lab keeps the blocks, and it is worth knowing how to request them: they are needed for a pathology review, immunohistochemistry and molecular tests.
Malignant tumor
A tumor whose cells can grow into nearby tissue and spread through the blood and lymph to form metastases elsewhere in the body. Malignant tumors are what people mean by cancer. The exact type can only be determined from a biopsy.
Benign tumor
A growth that stays where it started, does not invade nearby tissue and does not spread. It can still cause trouble by pressing on organs and is sometimes removed, but it is not cancer. A few benign growths can change over time, so the doctor decides whether follow-up is needed.
Carcinoma
Cancer that starts in epithelial cells, which line the skin, mucous membranes and internal organs. It is the most common group of cancers. The pathology report usually names the subtype, such as adenocarcinoma or squamous cell carcinoma.
Cancer that starts in gland cells, which make mucus and other fluids. Most cancers of the breast, lung, colon, stomach, pancreas and prostate are adenocarcinomas. The term describes the cell type, not the organ, so the organ of origin is stated separately.Read more
Cancer that starts in squamous cells, the flat cells that cover the skin and line several organs. It occurs in the skin, lung, esophagus, head and neck, cervix and anal canal. The cell type affects treatment choices, so it is always stated in the pathology report.Read more
Sarcoma
A malignant tumor of connective tissue, such as bone, muscle, fat, blood vessels or cartilage. Sarcomas are much rarer than carcinomas and include dozens of subtypes, so the diagnosis is ideally confirmed by a pathologist with sarcoma experience.
Melanoma
A malignant tumor that starts in melanocytes, the cells that make pigment. It most often begins in the skin, less often in mucous membranes or the eye. For advanced melanoma, testing the tumor for a BRAF mutation matters for treatment.
A tumor that starts in cells that release hormones in response to signals from the nervous system. It most often arises in the bowel, pancreas or lungs. Some grow slowly and some are aggressive; the grade and Ki-67 reflect this and shape the treatment plan.Read more
Abnormal cells that look like cancer but stay within the layer where they started and have not grown deeper. This is stage 0: it does not spread, but without treatment it may become invasive cancer. Ductal carcinoma in situ of the breast is a common example.Read more
Invasive cancerInfiltrating cancer
Cancer that has grown beyond the layer where it started into the surrounding tissue. Unlike carcinoma in situ, it is able to spread. The word ‘invasive’ does not mean the cancer has already spread: that is described by the stage.
Dysplasia
Cells in a tissue that look abnormal under the microscope but are not cancer. Dysplasia is graded as mild, moderate or severe. Severe dysplasia can progress to cancer, so it is usually treated or removed and then followed up.
A measure of how different the tumor cells look from normal cells. G1 is well differentiated, close to normal tissue and usually slower growing; G3 is poorly differentiated and more aggressive. Each cancer type has its own grading system, and grade is not the same as stage.Read more
Tumor cells that the pathologist sees inside small lymph or blood vessels near the tumor. These are not metastases, but they show the tumor has a route to spread. LVI is weighed when estimating the risk of recurrence and deciding on treatment after surgery.Read more
Tumor cells growing along or around nerves. It is seen only under the microscope and, in several cancer types, is linked to a higher risk of the cancer coming back locally. Doctors consider it alongside other factors when planning treatment after surgery.Read more
Describes whether any tumor was left behind after surgery. R0 means no tumor at the edges of the removed tissue under the microscope; R1 means tumor cells reach the edge microscopically; R2 means visible tumor remains. This shapes decisions about further surgery or radiotherapy.Read more
Primary tumor
The tumor in the organ where the cancer started. Metastases elsewhere are made of the same cells, so lung cancer that has spread to the liver is still lung cancer, not liver cancer. Treatment is based on the primary tumor.
Metastasis
A tumor deposit that has formed away from the primary tumor after cancer cells traveled through the lymph or blood. Metastases can be in regional lymph nodes or in distant organs. They usually mirror the primary tumor, but markers can change, so a metastasis is sometimes biopsied.
Multiple primary cancers
Two or more separate cancers in the same person, rather than one cancer with metastases. They may be found at the same time (synchronous) or at different times (metachronous). Pathology and marker testing help tell them apart, and this changes the treatment plan.
The international system for describing how far a cancer has spread. T is the size and extent of the primary tumor, N is involvement of regional lymph nodes, and M is distant metastasis. Together they give the stage. Each cancer type has its own rules.Read more
Prefixes that show how the TNM stage was set. c is clinical, based on examination and scans; p is pathological, based on the removed tumor and lymph nodes; yp is pathological after treatment given before surgery. ypTNM shows what was left after that treatment.Read more
Cancer stage
An overall measure of how far a cancer has spread, usually from 0 to IV. It is worked out from TNM: tumor size, lymph node involvement and distant metastases. Stage is one of the main factors in choosing treatment, along with the tumor type and its markers.
Regional lymph nodes
The lymph nodes closest to the tumor, where lymph from the affected organ drains first. Their status is the N in TNM. Cancer in regional lymph nodes is not the same as distant metastasis and does not by itself make a cancer stage IV.
Distant metastasesM1
Tumor deposits in organs far from the primary tumor, or in non-regional lymph nodes, for example in the liver, lungs or bones. They are recorded as M1 and usually mean stage IV. Treatment then most often centers on drug therapy.
Cancer that has spread to only a few sites, usually in one or two organs. For some tumor types, local treatment of each site with surgery or radiotherapy may be discussed alongside drug therapy. Whether this fits is decided by a tumor board.Read more
Locally advanced cancer
Cancer that has grown beyond its original site into nearby tissue or regional lymph nodes but has not spread to distant organs. Treatment is often combined, for example drug therapy or radiotherapy before surgery. The exact criteria depend on the cancer type.
Spread of cancer across the peritoneum, the thin lining of the abdominal cavity and organs. It is most common with cancers of the ovary, colon, rectum, stomach, pancreas and appendix. It can cause fluid to build up in the abdomen, called ascites.Read more
Cancer of unknown primaryCUP
A diagnosis in which cancer is found in the body but doctors cannot identify where it started. Immunohistochemistry, scans and molecular tests are used to look for the source. Even without a known primary, treatment can be chosen based on the tumor’s features.
IHC and molecular tests
ImmunohistochemistryIHC
A lab test that uses antibodies to stain specific proteins in a tumor sample. IHC helps identify the tumor type and origin and measures treatment markers such as ER, PR, HER2, Ki-67, PD-L1 and MMR proteins. It is done on tissue from the paraffin block.
Proteins in tumor cells that let the hormones estrogen and progesterone drive tumor growth. They are measured by IHC, most often in breast and endometrial cancer. If they are present, the cancer is called hormone receptor-positive and treatment usually includes hormone therapy.Read more
A protein on the cell surface; too much of it speeds up tumor growth. IHC scores it: 0 and 1+ are negative, 3+ is positive, and 2+ is borderline, so an ISH or FISH test is done to decide. HER2-positive cancer is treated with HER2-targeted drugs.Read more
A tumor scored HER2 1+ by IHC, or 2+ with no gene amplification on ISH. Technically this is HER2-negative cancer, but separate drug options now exist for this group. That is why the exact HER2 score, not just ‘negative’, matters to your doctor.Read more
A protein found in dividing cells. The report gives the percentage of tumor cells that stain for it: the higher it is, the faster the cells are dividing. There is no single cutoff for all cancers, and Ki-67 is read together with other findings, not on its own.Read more
Breast cancer whose cells have no estrogen or progesterone receptors and no excess HER2. Hormone therapy and HER2-targeted drugs do not work for it, so treatment usually centers on chemotherapy, with immunotherapy and other drugs added when appropriate.Read more
Subtypes of hormone receptor-positive breast cancer. Luminal A has hormone receptors, is HER2-negative and has low Ki-67; it usually grows more slowly. Luminal B has higher Ki-67 and is sometimes HER2-positive, and other treatment is often added to hormone therapy.Read more
A protein that helps tumors hide from the immune system. Its level is measured by IHC to guide decisions about immunotherapy. TPS is the share of stained tumor cells; CPS also counts stained immune cells. Which score and cutoff matter depends on the cancer type and the drug.Read more
Signs that the tumor’s DNA error-repair system is broken. dMMR is found by IHC as missing MMR proteins; MSI is found by a molecular test. They are most common in colorectal, stomach and endometrial cancers, and such tumors often respond well to immunotherapy.Read more
Tumor mutational burdenTMB
The number of DNA changes in a tumor, usually given per megabase (mut/Mb). It is measured with an NGS test. Tumors with many mutations are more likely to respond to some types of immunotherapy, so TMB is used as one of the biomarkers.
A gene for a receptor protein that signals cells to grow. EGFR mutations are found mainly in non-squamous non-small cell lung cancer. If a mutation is present, targeted therapy with an EGFR inhibitor is discussed, so the test is done before treating advanced disease.Read more
A gene whose rearrangement, or fusion with another gene, can drive tumor growth. In non-small cell lung cancer, an ALK-positive result opens the option of targeted therapy with ALK inhibitors. It is tested by IHC, FISH or NGS.Read more
ROS1
A gene whose rearrangement is found in a small share of non-small cell lung cancers and some other tumors. ROS1-positive cancer can be treated with targeted drugs, so ROS1 is part of the standard test set for advanced lung cancer.
A gene often mutated in colorectal, lung and pancreatic cancers. In colorectal cancer, a KRAS mutation means anti-EGFR antibodies will not work. Targeted drugs exist for some specific variants, such as KRAS G12C.Read more
A gene for a protein that relays growth signals inside the cell. BRAF mutations, most often the V600E variant, are tested for in melanoma and in colorectal, lung and thyroid cancers. A mutation may open the option of targeted therapy and also affects the outlook.Read more
Genes that help repair damaged DNA. Inherited mutations in them raise the risk of breast, ovarian, pancreatic and prostate cancer. A BRCA mutation found in the tumor or in blood may make PARP inhibitors an option and is also important for relatives.Read more
A molecular test that checks many tumor genes at once for mutations, rearrangements, MSI and TMB. It is done on tissue from the paraffin block or on blood. It avoids using up tissue and time on one-gene-at-a-time testing.Read more
FISHFluorescence in situ hybridization
A lab method in which glowing probes attach to a specific stretch of DNA in cells. FISH shows whether a gene has extra copies or has been rearranged. In cancer care it is most often used to settle a HER2 2+ result and to look for ALK and ROS1 rearrangements.
A test on blood or another body fluid that looks for tumor DNA or tumor cells. It is used to find mutations when tissue is scarce or a biopsy is risky, and to track changes in the tumor during treatment. A negative result does not rule out a mutation, so tissue testing may still be needed.Read more
Somatic and germline mutationsInherited mutation
A somatic mutation arises in the tumor cells and is not passed on to children. A germline, or inherited, mutation is present in every cell from birth and may run in the family. Tumor testing picks up both, and a blood or saliva test tells them apart.
Scans and tumor markers
CT scanComputed tomography
An X-ray scan that builds cross-sectional images of the body. In cancer care, CT is the main way to find lesions, work out the stage and compare tumor size before and during treatment. It usually uses IV contrast, so you will be asked about kidney function and contrast allergy.
MRIMagnetic resonance imaging
A scan that uses a magnetic field instead of X-rays. It shows soft tissue better than CT, so it is preferred for the liver, pelvis, breast, spine and brain. It takes longer than CT and may not be possible with a pacemaker or certain metal implants.
PET-CT
A PET scan combined with CT. A radioactive tracer, most often FDG, is injected, and the scanner shows where cells take it up actively. It helps find distant spread and judge tumor activity, but inflammation also lights up, so findings are checked against other tests.
The maximum standardized uptake value: how strongly the most active spot in a lesion takes up tracer on PET-CT. Higher means more active tissue. It is not a diagnosis on its own: inflammation can score high and some cancers score low. Values are best compared over time on the same scanner.Read more
FDG18F-fluorodeoxyglucose
The most widely used PET-CT tracer, a radioactively labeled form of glucose. Many cancer cells use glucose faster than normal cells, so they show up brighter on the scan. That is why you are asked to fast for several hours beforehand and your blood sugar is checked.
Bone scanBone scintigraphy
A whole-skeleton scan after a small dose of radioactive tracer that collects where bone is actively remodeling. It is used to look for cancer that has spread to bone. Fractures, arthritis and inflammation also show up, so suspicious areas are often checked with CT or MRI.
Mammogram
An X-ray of the breasts and the main breast cancer screening test. Results are usually reported using the BI-RADS system: the category shows how suspicious a finding is and what comes next — routine follow-up, extra imaging or a biopsy.
Focal lesion
A descriptive phrase in a CT, MRI or ultrasound report: a defined area in an organ that looks different from the surrounding tissue. It does not mean cancer by itself — it may be a cyst, a hemangioma or a scar. Its nature is clarified by its features, how it changes over time or a biopsy.
Lymphadenopathy
Enlarged lymph nodes found on exam or imaging. Causes include infection, inflammation, a reaction to treatment or cancer. Doctors look at the size, shape, internal structure and location of the node; if in doubt, it is sampled with a needle or removed for pathology.
Tumor markers
Substances in the blood whose levels can rise with certain cancers. One marker is not enough to diagnose cancer: levels also rise in benign conditions and can be normal when cancer is present. Their main use is tracking trends in someone already diagnosed.
A tumor marker used mostly in colon and rectal cancer, to monitor treatment and follow-up afterwards. It can also be raised in smokers and in inflammatory bowel disease, liver and lung conditions, so it is read only together with symptoms and scans.Read more
A tumor marker used mainly in ovarian cancer to judge response to treatment and spot recurrence. It also rises without cancer: with endometriosis, fibroids, periods, pregnancy or inflammation of the abdominal lining. It is not recommended as a stand-alone screening test for women without symptoms.Read more
A breast cancer tumor marker. It is used mainly in metastatic disease to track trends during treatment. It is not used for early detection or routine follow-up after curative treatment, since it is often normal with small tumors.Read more
A tumor marker most often measured in pancreatic and bile duct cancer. It also rises with blocked bile ducts, pancreatitis and cholangitis. Some people, because of their Lewis blood group type, do not make CA 19-9 at all, so a normal result does not rule out a tumor.Read more
A tumor marker in liver cancer and germ cell tumors. It helps with diagnosis and with following the response to treatment. It also rises with hepatitis, cirrhosis and pregnancy, so one result is a reason for tests, not a diagnosis.Read more
HE4 is an ovarian cancer tumor marker. ROMA is an index calculated from HE4, CA-125 and menopausal status: it shows the probability that an ovarian mass is malignant and helps decide where to have surgery. The diagnosis is made only by pathology.Read more
A tumor marker, a fragment of cytokeratin 19. It is used in non-small cell lung cancer to help monitor for recurrence. It can't diagnose cancer and is only informative if it was raised before treatment.Read more
PSAProstate-specific antigen
A protein made by the prostate. The PSA blood test is used for early detection of prostate cancer and for follow-up after treatment. Levels also rise with an enlarged prostate, prostatitis, cycling or prostate massage, so a biopsy decision is not based on one number.
Contrast enhancement
A phrase from a CT or MRI report: after contrast was injected, an area became brighter than the tissue around it. Tumors often have their own blood supply and enhance in a typical way, but so do inflammation, vascular lesions and scars. The pattern matters more than the fact itself.
International criteria for measuring how solid tumors respond, based on CT or MRI. The doctor picks measurable lesions and compares the sum of their sizes: a drop of at least 30% is a partial response; growth of 20% or more (and at least 5 mm) or new lesions is progression.Read more
Complete response
A result where all tumor lesions visible on scans have disappeared (by RECIST, all target lesions are gone). It is a strong result but not a guarantee of cure: cells can remain below what scans can detect, so follow-up continues.
Partial response
The tumor has shrunk noticeably but has not disappeared. By RECIST, the sum of the measured lesions has fallen by at least 30% from baseline and there are no new lesions. It usually means the treatment is working and it is continued.
On follow-up scans the tumor has not shrunk enough to count as a partial response and has not grown enough to count as progression. In advanced cancer this is often a good result: the disease is being held in check, and treatment usually continues.Read more
The tumor is growing or new lesions have appeared despite treatment. By RECIST, the sum of the measured lesions has grown by 20% or more (at least 5 mm), or a new lesion has appeared. It is usually a reason to discuss switching to another line of therapy.Read more
When, during immunotherapy, a tumor first looks bigger on scans or new spots appear, and then it shrinks. The growth comes from immune cells and swelling, not real cancer growth. It is uncommon, so decisions rely on a repeat scan and how the person is feeling.Read more
Assessing treatment effect on PET-CT: how much the tumor’s activity, its tracer uptake, has fallen. Activity can drop before the tumor gets smaller. Separate criteria such as PERCIST or the Deauville scale are used to keep this consistent.Read more
Changes in the tumor after chemotherapy, radiation or targeted therapy that the pathologist sees in removed tissue: how many cancer cells died and how many remain. In Russia it is often graded with the Lavnikova scale from I to IV; grade IV means no viable tumor cells were found.Read more
After neoadjuvant treatment and surgery, no viable invasive cancer is found in the removed tissue and lymph nodes. In breast cancer, especially HER2-positive and triple-negative, pCR is linked to a better outlook and shapes the choice of treatment after surgery.Read more
A period when signs of cancer have decreased (partial remission) or can no longer be detected by tests (complete remission). With solid tumors, doctors more often say ‘complete response’ or ‘no evidence of disease’. Remission is not a guarantee that cancer will not come back.Read more
RecurrenceRelapse
Cancer returning after treatment, following a period with no signs of disease. It can be local (in the same place), regional (in nearby lymph nodes) or distant (metastases). The plan depends on the type of recurrence, the time since treatment and what was already used.
Disease-free survivalDFS, RFS
A clinical trial measure: the share of patients without recurrence at a given time after curative treatment. It is used to compare adjuvant treatments. It describes groups, so applying it to one person takes care.
Overall survivalOS
The share of patients alive at a given time after diagnosis or the start of treatment, whatever the cause of death. It is the main and most rigorous measure of treatment benefit in trials. It describes a group, not one person’s outlook.
The time by which half the patients in a study are still alive and half are not. It is not ‘how long is left’: many people live much longer than the median, and trial data reflect treatment from past years. It is better used to compare treatments than as a personal forecast.Read more
Treatment
Chemotherapy
Treatment with drugs that damage rapidly dividing cells, cancer cells first of all. It is given by IV or as pills, in cycles with breaks for recovery. It can be used before surgery, after it, or as the main treatment for advanced cancer.
Targeted therapy
Drugs that act on a specific molecular target in the tumor — an altered protein or gene such as EGFR, ALK or HER2. They work only when the target is present, so IHC or molecular tumor testing is needed before they are prescribed.
Immunotherapy
Treatment that helps your own immune system recognize and attack cancer. In medical oncology this mostly means checkpoint inhibitors. It does not work for every tumor; its side effects come from inflammation in healthy organs and need close monitoring.
Hormone therapyEndocrine therapy
Treatment for cancers whose growth depends on hormones, mainly ER/PR-positive breast cancer and prostate cancer. The drugs lower hormone production or block hormones from acting on the tumor. It is often taken long term, for years.
Neoadjuvant therapy
Drug treatment or radiation given before surgery. The aims are to shrink the tumor, make surgery possible or smaller, and see how the tumor responds to the drugs. The response found in the removed tissue helps decide whether more treatment is needed after surgery.
Adjuvant therapy
Treatment after curative surgery, when no visible tumor remains. Its job is to destroy any cells that may be left and lower the risk of recurrence. Not everyone needs it: the decision depends on stage, tumor biology and expected benefit weighed against side effects.
The order number of a treatment regimen for advanced cancer. First line is where treatment starts; second line is what follows if the cancer progresses or the first is not tolerated, and so on. The line number shapes which treatments and clinical trials are available.Read more
Maintenance therapy
Continuing treatment, often in a lighter form, after the main phase has produced a response or stable disease. The goal is to keep the disease under control for longer. Note that the Russian term is sometimes also used for supportive care — managing side effects — so it is worth asking which is meant.
Palliative therapy
Treatment aimed at extending life and keeping its quality when cure is not possible. It includes anticancer drugs, pain relief, symptom control and psychological support. Palliative does not mean ‘final’: many people receive it for years.
Chemotherapy cycle and course
A cycle is a round of drugs plus the rest period before the next one, for example every 3 weeks. ‘Course’ is used loosely for either one cycle or the whole series. In your records, look at the number of cycles, the interval and the doses rather than the word itself.
Drug combinations with a set order and schedule. They are often named by acronyms: FOLFOX is folinic acid, fluorouracil and oxaliplatin; AC is doxorubicin and cyclophosphamide. The regimen is chosen based on the tumor type, stage and the patient’s condition.Read more
Immune checkpoint inhibitors
Immunotherapy drugs that take the ‘brakes’ off immune cells by blocking PD-1, PD-L1 or CTLA-4. T cells then attack the tumor more actively. They are used in melanoma, lung, kidney, bladder and other cancers; benefit is often linked to PD-L1 and MSI status.
Targeted pills (palbociclib, ribociclib, abemaciclib) that slow cancer cell division. They are used for HR-positive, HER2-negative breast cancer together with hormone therapy. A common side effect is a drop in neutrophils, so regular blood tests are part of treatment.Read more
PARP inhibitors
Targeted drugs, such as olaparib, that stop cancer cells from repairing DNA damage. They work especially well when another repair pathway in the tumor is already broken, as with BRCA1/2 mutations. They are used in ovarian, breast, pancreatic and prostate cancer.
Monoclonal antibodies
Protein drugs designed to bind one specific target, such as HER2 (trastuzumab), EGFR (cetuximab) or PD-1 (pembrolizumab). They are given by IV or under the skin. Some are targeted therapy, some are immunotherapy. Their generic names end in ‘-mab’.
Biosimilar and generic
A generic is a copy of a chemical drug with the same active ingredient. A biosimilar is a version of a biologic drug, such as an antibody: the molecule cannot be identical, so a biosimilar goes through comparison studies of efficacy and safety against the original.
PortImplanted port, port-a-cath
A small device under the skin, usually below the collarbone, with a catheter into a large vein. Chemotherapy is given and blood is drawn through it without new needle sticks in the arms. It helps with long treatment and vein-irritating drugs, and needs regular flushing and care.
Radiation therapyRadiotherapy
Treatment with ionizing radiation that damages the DNA of cancer cells in a defined area. It is used alone, with chemotherapy, before or after surgery, and to ease symptoms such as pain from bone metastases. It acts locally.
ChemoradiationChemoradiotherapy
Radiation therapy and chemotherapy given at the same time. The drugs make the tumor more sensitive to radiation. It is standard for several cancers, such as rectal, cervical, esophageal and locally advanced lung cancer. It is harder to tolerate than either treatment alone.
Tumor boardMultidisciplinary team meeting
A joint case review by cancer specialists from different fields — surgeon, medical oncologist, radiation oncologist, often with a pathologist and radiologist. The outcome is a written treatment plan. In Russia, a tumor board decision is required to set the treatment plan for a cancer patient.
Clinical trial
A research study in patients that tests a new drug, combination or approach. Taking part is voluntary and requires signed informed consent; you can leave at any time. For some patients it is a way to get treatment not yet available in routine practice.
A 0 to 5 scale of a patient’s general condition: 0 — fully active; 1 — limited only in strenuous activity; 2 — able to self-care but unable to work; 3 — in bed or a chair more than half the day; 4 — completely bedbound; 5 — death. It affects which treatment is chosen and how intensive it is.Read more
Immunotherapy — an anti-PD-1 antibody, an immune checkpoint inhibitor. Used in lung cancer, melanoma, triple-negative breast cancer, MSI-H tumors and many others. Given by drip every 3 or 6 weeks.Read more
Immunotherapy — an anti-PD-1 antibody. Used in melanoma, lung, kidney, esophageal, stomach and other cancers, including together with ipilimumab. Its side effects come from inflammation of healthy organs.Read more
A targeted antibody against HER2. The backbone of treatment for HER2-positive breast and stomach cancer. It can reduce how well the heart pumps, so echocardiograms are done regularly during treatment.Read more
An antibody against HER2 given together with trastuzumab and chemotherapy in HER2-positive breast cancer — before surgery, after it and in metastatic disease. A common side effect is diarrhea.Read more
A conjugate: an antibody to HER2 linked to a chemotherapy drug. It works in HER2-positive and HER2-low breast cancer and some other tumors. The lungs need monitoring because of the risk of interstitial lung disease.Read more
A targeted antibody that blocks the growth of tumor blood vessels (VEGF). Used with chemotherapy in colon, lung, ovarian, cervical and other cancers. It can raise blood pressure and slow wound healing.Read more
Targeted tablets for non-small cell lung cancer with an EGFR mutation — after surgery and in advanced cancer. Common side effects are rash, diarrhea and nail changes.Read more
Hormone therapy that blocks estrogen receptors. Used in hormone receptor-positive breast cancer, more often before menopause, usually for 5–10 years. It can cause hot flashes and, rarely, blood clots and endometrial changes.Read more
Hormone therapy after menopause: the drugs lower estrogen production. Used in hormone receptor-positive breast cancer, often together with CDK4/6 inhibitors. Common side effects are joint pain and bone loss.Read more
Chemotherapy in tablets: in the body it turns into fluorouracil. Used in colon, breast and stomach cancer. The main side effects are hand-foot syndrome and diarrhea.Read more
A taxane chemotherapy drug. Used in breast, ovarian, lung, stomach and other cancers — weekly or every 3 weeks. Allergy premedication is needed before the infusion; numb fingers are a common side effect.Read more
A taxane chemotherapy drug. Used in breast, prostate, stomach and lung cancer. It often lowers neutrophils and causes fluid retention and nail changes.Read more
Chemotherapy drugs that damage tumor cell DNA — the backbone of many regimens. Cisplatin is hardest on the kidneys and hearing, carboplatin on platelets, and oxaliplatin causes neuropathy and cold sensitivity.Read more
A chemotherapy regimen: oxaliplatin, fluorouracil and leucovorin every 14 days, with a 46-hour pump. The main regimen in colon cancer, also used in stomach and esophageal cancer.Read more
A chemotherapy regimen: oxaliplatin by drip every 21 days plus capecitabine tablets for 14 days. Comparable to FOLFOX in effectiveness, but without a pump.Read more
An intensive four-drug regimen: fluorouracil, leucovorin, irinotecan and oxaliplatin. Mainly used in pancreatic cancer in patients in good general condition.Read more
A breast cancer chemotherapy regimen: 4 cycles of doxorubicin with cyclophosphamide, then paclitaxel or docetaxel. The heart is checked before doxorubicin.Read more
A low level of neutrophils, the white blood cells that are the first defense against bacteria. A common effect of chemotherapy; the lowest point usually comes about 7 to 14 days after treatment. It raises infection risk, so temperature is watched closely and the next cycle may be delayed.Read more
Fever with a low neutrophil count. It is an emergency: an infection in someone with weak defenses can turn serious fast. If you develop a fever during chemotherapy, contact your care team right away or call your local emergency number — do not wait.Read more
Leukopenia
A low total white blood cell count, common after chemotherapy. For infection risk, the absolute neutrophil count matters more than the total white count, which is why doctors look at the differential in the blood test.
A low platelet count; platelets help blood clot. Signs include easy bruising, bleeding gums and tiny red dots on the skin. Causes include chemotherapy and cancer in the bone marrow; with a marked drop, treatment may be delayed or adjusted.Read more
Anemia
Low hemoglobin and red blood cells. In people with cancer it can come from the disease itself, blood loss, iron deficiency, chemotherapy or radiation. It causes tiredness, shortness of breath and pale skin. Treatment depends on the cause: iron, blood transfusion or other options.
Peripheral neuropathy
Damage to peripheral nerves: numbness, tingling or burning in the fingers and toes, clumsiness. It is caused by some chemotherapy drugs — taxanes, platinum drugs (especially oxaliplatin) and vinca alkaloids. Tell your doctor about the first symptoms: sometimes the dose is adjusted.
Redness, swelling, soreness and peeling of the palms and soles, and in severe cases cracks and blisters. Typical with capecitabine, fluorouracil, liposomal doxorubicin and some targeted drugs. Prevention includes moisturizing and avoiding friction and hot water.Read more
Inflammation of the mucous membranes during chemotherapy or radiation. Stomatitis affects the mouth: pain, redness, sores, trouble eating. Mucositis is broader and includes the gut lining. A soft toothbrush, frequent rinsing and avoiding spicy food help; severe pain needs treatment from your doctor.Read more
Side effects of immunotherapy in which the activated immune system inflames healthy organs. Examples include colitis, pneumonitis, hepatitis, thyroid problems and rash. They can appear at any time, even after treatment ends. Report new symptoms — diarrhea, cough, breathlessness — to your doctor right away.Read more
Heart damage from cancer treatment: weaker pumping, irregular rhythm, high blood pressure. It is most often linked to anthracyclines, anti-HER2 drugs such as trastuzumab and radiation near the heart. That is why heart function is checked with echocardiogram and ECG before and during such treatment.Read more
A common side effect of chemotherapy, targeted drugs and immunotherapy. Dangerous because of dehydration. With frequent stools, blood, fever or dizziness, contact your doctor straight away; on immunotherapy, diarrhea can be a sign of colitis.Read more
An acne-like rash on the face, chest and back during treatment with EGFR inhibitors (osimertinib, cetuximab and others). It isn't acne, and acne products make it worse. A mild rash needs no dose change; with a severe one treatment is paused.Read more
Clots in the veins of the legs or arms or in the lungs (pulmonary embolism). Cancer and its treatment raise the risk. Swelling and pain in one limb, sudden breathlessness or chest pain are reasons to see a doctor urgently. Treated with anticoagulants.Read more
The US National Cancer Institute scale for side effect severity. Grade 1 is mild, 2 moderate, 3 severe or needing hospital care, 4 life-threatening, 5 death related to the adverse event. The grade guides whether to continue treatment, lower the dose or take a break.Read more
Drugs (filgrastim, pegfilgrastim) that push the bone marrow to make neutrophils faster. They are given after chemotherapy with a high risk of febrile neutropenia, or if it has already happened. A common side effect is aching bone pain.Read more
Cachexia
Wasting in cancer: loss of weight, muscle and strength that ordinary extra eating cannot fully reverse. It is driven by inflammation and metabolic changes caused by the tumor. It makes treatment harder to tolerate, so weight and nutrition are worth raising with your doctor from the start.
Hair lossAlopecia
Hair loss during chemotherapy depends on the drugs: some cause complete loss, others thinning or almost none. Hair usually starts to grow back a few weeks after treatment ends. With some regimens, scalp cooling can reduce hair loss.
This is reference information and not a substitute for medical advice. Your doctor interprets each value in the context of your whole situation.